.svg)
Your guide to Ozempic®, Wegovy®, Zepbound®, and Mounjaro®
About 1 in 8 Americans has reported using a GLP-1 medication to treat diabetes or for weight-loss support. Its use for weight loss has become so popular that brand-name medications like Ozempic® come up regularly in everyday conversations.
However, while GLP-1 medications have similar benefits, they are not interchangeable. If you have ever wondered what the difference between Ozempic®, Wegovy®, Zepbound®, and Mounjaro® actually is, this article will be your guide.
What Ozempic®, Wegovy®, Zepbound®, and Mounjaro® have in common
Ozempic®, Wegovy®, Zepbound®, and Mounjaro® have all been used to help people lose weight, as well as treat other conditions like type 2 diabetes. Here are the main ways these medications are similar:
- GLP-1–based medication: Each drug mimics the GLP-1 hormone, which helps regulate blood sugar, insulin release, appetite, and satiety. Tirzepatide also activates the GIP pathway, which may provide further support.
- Injectable delivery method: All are administered as once-weekly injections.
- Weight-loss effects: Each medication has been shown to support weight loss, though not all of them are officially FDA-approved for that purpose.
- Side effects: Nausea, vomiting, diarrhea, and other gastrointestinal symptoms can happen with any of these medications.
People take these medications for many of the same reasons, but not everyone responds to them in the same way. This is where the differences become especially important.
How GLP-1 medications are different
The differences between GLP-1 medications are more subtle, but no less impactful. Let’s break them down by medication.
Ozempic®
- Active ingredient: Semaglutide
- Dosing schedule: Subcutaneous injection once a week. Dosage typically starts at 0.25 mg per week and gradually increases to 1 mg weekly. See a sample Ozempic® dosing schedule here.
- Dosage form: Pens that contain multiple doses. Before each injection, you attach a new needle to the pen, and then discard after your shot. The number of doses per Ozempic® pen varies depending on your dosage.
- What it’s approved for: Ozempic® is FDA-approved for type 2 diabetes, and is sometimes prescribed “off-label” for weight loss.
Like the natural GLP-1 hormone, Ozempic® stimulates insulin release and lowers blood sugar levels, but it stays in your system longer than natural GLP-1. This slows the gastric emptying process so you feel full for longer. As a result, it can be easier to avoid overeating, and food noise and cravings can be easier to manage.
Wegovy®
- Active ingredient: Semaglutide
- Dosing schedule: Subcutaneous injection once a week. Dosage typically starts at 0.25 mg per week and gradually increases to up to 2.4 mg weekly. See a sample Wegovy® dosing schedule here.
- Dosage form: Single-use pens with needles already attached.
- What it’s approved for: Wegovy® is FDA-approved for chronic weight management and, as of March 2024, is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults with cardiovascular disease and obesity, which helps explain differences in labeling and payer coverage between Wegovy® and semaglutide products approved for diabetes.
Ozempic® and Wegovy® have more similarities than differences. The main difference is FDA approval. Ozempic® is specifically approved to treat type 2 diabetes, while Wegovy® is approved for weight management. That said, both medications have been shown to help people achieve meaningful weight loss.
Zepbound®
- Active ingredient: Tirzepatide
- Dosing schedule: Subcutaneous injection once a week. Dosing typically starts at 2.5 mg and gradually increases to up to 10 mg weekly. See a sample Zepbound® dosing schedule here.
- Dosage form: Single-use pens with needles already attached.
- What it’s approved for: Zepbound® is FDA-approved for weight management in adults with obesity or overweight plus a weight-related condition, reflecting its formal indication for weight loss separate from its diabetes brand.
The active ingredient in Zepbound®, tirzepatide, has a dual mechanism of action. This means that it mimics GLP-1 and another hormone, GIP, which also plays a role in satiety and insulin secretion.
Mounjaro®
- Active ingredient: Tirzepatide
- Dosing schedule: Subcutaneous injection once a week. Dosing typically starts at 2.5 mg and gradually increases to up to 10 mg weekly.
- Dosage form: Single-use pens with needles already attached.
- What it’s used for: Mounjaro® is FDA-approved for type 2 diabetes, but may be prescribed off-label for weight management. See a sample Mounjaro® dosing schedule here.
With the same active ingredient, Mounjaro® and Zepbound® work the same way and have similar dosing schedules. The main difference between the two is FDA approval types, but both have been used to help treat weight loss.
Which GLP-1 is best for weight loss?
Ozempic®, Wegovy®, Zepbound®, and Mounjaro® have all shown to help people lose weight. In the recent SURMOUNT-5 trial, which is the first to compare semaglutide and tirzepatide head-to-head, the study found that participants lost an average of 50 pounds on tirzepatide and 33 pounds on semaglutide. In the phase 3b SURMOUNT-5 trial published in the New England Journal of Medicine, participants treated with tirzepatide lost a mean of about 20.2% of body weight versus 13.7% with semaglutide at 72 weeks. SURMOUNT-5 NEJM summary.
The better results on tirzepatide are likely due to the dual mechanism of action. Ongoing research continues to clarify the unique benefits of semaglutide versus tirzepatide.
GLP-1 medication should be paired with a balanced, healthy diet and regular exercise, regardless of which treatment you are on. Studies across the board show that those who develop sustainable habits are more likely to get the results they are hoping for, and to keep the weight off if they decide to discontinue treatment.
Individual results vary, so what works well for someone else may not work as well for you. Having multiple GLP-1 options is helpful because it increases the chances of finding a solution suited to your needs and goals.
If you want support without injections, Shed also offers needle-free options you can discuss with your provider:
- Learn about GLP-1 liquid drops: https://www.tryshed.com/products/product/glp-1-liquid-drops
- Explore a gentler, microdose GLP-1 approach: https://www.tryshed.com/products/product/microdose-glp-1
- Read more about non-injectable GLP-1 lozenges and what to expect: https://www.tryshed.com/blog/post/glp-1-lozenges-a-new-way-to-deliver-a-powerful-hormone
How to know which GLP-1 is right for you
Your provider will go over your options with you before you start treatment. Some of the factors that will need to be taken into consideration include:
- BMI and comorbid health status
- Health goals
- Side effect tolerance
- Insurance and cost
- Dosing schedule and administration preferences
You can also review Shed’s GLP-1 injection programs to understand formats, titration, and support: https://www.tryshed.com/products/product/glp-1-injections.
Always consult with a licensed medical provider before starting GLP-1 treatment or making major changes to your health regimen.
FAQs about Wegovy®, Ozempic®, Zepbound®, and Mounjaro®
What is the difference between Ozempic® and Wegovy®?
-
Both contain the same active ingredient semaglutide, but are approved for different uses. Ozempic® is FDA-approved for type 2 diabetes, while Wegovy® is FDA-approved for chronic weight management. Your Shed clinician will make a recommendation based on goals, side effects, and medical history. You can also explore the Shed Membership at https://www.tryshed.com/products/product/wegovy.
How is Mounjaro® different from Zepbound®?
-
Both contain the same active ingredient tirzepatide and have similar dosing schedules, but are approved for different uses. Mounjaro® is FDA-approved for type 2 diabetes, while Zepbound® is approved for weight management. Shed providers can evaluate your history and recommend the most appropriate option.
Which medication causes the most weight loss?
-
Clinical trials suggest that tirzepatide can lead to greater average weight loss than semaglutide at higher doses. Some studies report up to about 20 percent of body weight lost with tirzepatide and about 15 percent with higher-dose semaglutide. Individual results vary. Your Shed plan will incorporate nutrition and activity to support sustained results.
Do I have to be diabetic to take a GLP-1?
-
No. Wegovy® and Zepbound® are approved for adults who have obesity or overweight plus another health condition, even if you do not have diabetes. Shed clinicians assess BMI, comorbid conditions, and prior interventions before prescribing.
How long do I have to take Ozempic®, Wegovy®, Mounjaro®, or Zepbound®?
-
These medications are meant for long-term use. Many people regain weight and see glucose levels rise within a few months after stopping treatment. Shed emphasizes Health Coaching alongside medication so you build habits that support maintenance if you eventually discontinue.
Does insurance cover GLP-1 medications?
-
Insurance coverage varies widely. Coverage is more likely for diabetes indications. Weight-management coverage often requires prior authorization and documentation. The U.S. administration is considering a pilot program that would allow Medicare and Medicaid plans to cover GLP-1 for weight loss. If you do not qualify for coverage, Shed offers clear, upfront pricing.
How do side effects compare between semaglutide and tirzepatide?
-
Both can cause gastrointestinal symptoms like nausea, vomiting, diarrhea, or constipation, especially during dose increases. Some patients report similar tolerance across agents, while others do better on one molecule. Shed clinicians recommend simple strategies such as smaller meals and avoiding greasy foods during titration, and will adjust your plan if symptoms persist.
What dosing schedules and pen formats should I expect?
-
All four are once-weekly subcutaneous injections. Ozempic® uses multi-dose pens, while Wegovy®, Zepbound®, and Mounjaro® come in vials or single-use pens with attached needles. For those who prefer to avoid needles, Shed offers alternatives like GLP-1 liquid drops at https://www.tryshed.com/products/product/glp-1-liquid-drops and a GLP-1 Lozenges at https://www.tryshed.com/products/product/glp-1-lozenges.
Why might tirzepatide lead to greater weight loss than semaglutide?
-
Tirzepatide activates both GLP-1 and GIP receptors, which may enhance appetite control and energy expenditure beyond GLP-1 alone. In head-to-head research, this dual mechanism has been associated with larger average weight reductions. Your Shed provider will weigh benefits against your medical history and goals.
What practical steps does a healthcare provider take to determine eligibility and choose among these medications?
-
Clinicians look at BMI, medical history, prior weight-loss attempts, and relevant labs. They review contraindications such as pregnancy or certain thyroid cancers, discuss side effects and preferences, and consider payer rules.
